On the marketing front, Hackman said the company is expanding efforts to activate young adult testicular cancer patients and plans to launch an initiative tied to the Indy 500 in May in partnership with a testicular cancer advocacy group. He also said Fennec expects a significant presence at the ASCO meeting in Chicago later this year.Management said conversion rates improved over the course of the year, citing an increase from 50% in the first quarter to 70% in the fourth quarter. Hackman said these result ...

Fennec Pharmaceuticals (NasdaqCM:FENC) Q4 2025 Earnings call March 24, 2026 08:30 AM ET Company Participants Jeff Hackman - CEO Pierre S. Sayad - Chief Medical Officer Robert Andrade - CFO Conference Call Participants Chase Knickerbocker - Senior Research Analyst Madison El-Saadi - Healthcare Equity Research Analyst Raghuram Selvaraju - Managing Director and Equity Research Analyst None - Analyst None - Analyst Operator Good morning, ladies and gentlemen. Welcome to Fennec Pharmaceuticals' fourth quarter an ...

Fennec Pharmaceuticals (NasdaqCM:FENC) Q4 2025 Earnings call March 24, 2026 08:30 AM ET Company ParticipantsJeffrey S. Hackman - CEOPierre S. Sayad - CMORobert Andrade - CFOConference Call ParticipantsChase Knickerbocker - Senior Research AnalystMadison El-Saadi - Healthcare Equity Research AnalystRaghuram Selvaraju - Managing Director and Equity Research AnalystSudhanva Nathan - AnalystNone - AnalystOperatorGood morning, ladies and gentlemen. Welcome to Fennec Pharmaceuticals' fourth quarter and full year ...